Semaglutide, the active ingredient in brand names like Ozempic® and Wegovy® has quickly become one of the most widely prescribed medications for weight loss and type 2 diabetes management. Semaglutide has helped many people achieve lasting health … Read more
Planning your 2025 weight loss journey? Depending on your plan, FSA and/or HSA funds may be eligible to use with prescription weight loss medications. If not, you still have flexible ways to manage costs. Whether you’re considering … Read more
In today’s business world, healthy employees are a key driver of company success. As more employers recognize this, the demand for effective corporate wellness programs continues to rise. Ivím Health is leading the charge with its innovative … Read more
For those considering Wegovy® (semaglutide), Ozempic® (semaglutide), or compounded semaglutide for weight loss or as a treatment option for type 2 diabetes management, gaining clarity on the financial implications is important. This overview examines costs with insurance … Read more
FDA notice on Zepbound™/Mounjaro® shortage: On December 19th, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has ended. Patients may continue receiving essential copies through … Read more
At Ivím Health, our mission is to deliver unparalleled, personalized care that goes far beyond basic healthcare—and our membership model allows us to do just that. We’re proud to offer so much more than just weight loss … Read more
Initially developed as a treatment for type 2 diabetes, Ozempic® (semaglutide) has emerged as a transformative solution for weight loss. Semaglutide, the active ingredient in Ozempic®, has shown significant results in clinical trials. Research reveals that adults … Read more
While GLP-1 medication provides a phenomenal jumpstart for a weight loss journey, an integral part of achieving long-term results is developing healthy habits along the way. Diet and exercise are two common goals people set to improve, … Read more
FDA notice on Zepbound®/Mounjaro® shortage: On October 2, 2024, the U.S. Food and Drug Administration determined that the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, had ended. (Read more) Schedule a visit with an Ivim … Read more
Introduction An online weight loss prescription has emerged as a convenient an accessible option for individuals seeking professional guidance in their weight loss journey. In recent years, these virtual platforms have gained significant popularity. Their convenience, ease … Read more
